Overview

Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

Schering-Plough

Treatments:

Interferon alfacon-1
Interferon-alpha
Interferons